ARTICLE | Clinical News
TP10: Completed Phase II study enrollment
January 17, 2000 8:00 AM UTC
Avant Immunotherapeutics Inc. (AVAN), Needham, Mass. Product: TP10 Business: Cardiovascular Therapeutic category: Immune modulation Target: Complement Description: Soluble form of complement receptor...